StocksFundsScreenerSectorsWatchlists
IRMD

IRMD - iRadimed Corp Stock Price, Fair Value and News

43.37USD+0.78 (+1.83%)Market Closed

Market Summary

IRMD
USD43.37+0.78
Market Closed
1.83%

IRMD Stock Price

View Fullscreen

IRMD RSI Chart

IRMD Valuation

Market Cap

549.2M

Price/Earnings (Trailing)

31.94

Price/Sales (Trailing)

8.38

EV/EBITDA

22.19

Price/Free Cashflow

91.16

IRMD Price/Sales (Trailing)

IRMD Profitability

Operating Margin

76.50%

EBT Margin

33.16%

Return on Equity

24.07%

Return on Assets

18.66%

Free Cashflow Yield

1.1%

IRMD Fundamentals

IRMD Revenue

Revenue (TTM)

65.6M

Rev. Growth (Yr)

17.42%

Rev. Growth (Qtr)

5.74%

IRMD Earnings

Earnings (TTM)

17.2M

Earnings Growth (Yr)

23.58%

Earnings Growth (Qtr)

-10.41%

Breaking Down IRMD Revenue

Last 7 days

-2.3%

Last 30 days

-4.9%

Last 90 days

-6.7%

Trailing 12 Months

16.3%

How does IRMD drawdown profile look like?

IRMD Financial Health

Current Ratio

4.65

IRMD Investor Care

Shares Dilution (1Y)

0.55%

Diluted EPS (TTM)

1.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202356.5M59.9M63.0M65.6M
202244.9M47.8M50.3M53.3M
202132.3M35.3M38.5M41.8M
202038.8M36.3M34.1M31.7M
201931.8M33.6M36.0M38.5M
201825.0M26.9M28.8M30.4M
201728.7M24.4M22.4M23.1M
201633.6M35.8M35.3M32.5M
201519.1M22.0M26.4M31.6M
201412.4M13.5M14.6M15.7M
201300011.3M

Tracking the Latest Insider Buys and Sells of iRadimed Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 27, 2023
susi roger e.
sold
-232,547
46.5094
-5,000
ceo, president, chairman
Dec 26, 2023
susi roger e.
sold
-230,000
46.00
-5,000
ceo, president, chairman
Dec 21, 2023
susi roger e.
gifted
-
-
-300,000
ceo, president, chairman
Dec 19, 2023
susi roger e.
sold
-225,696
45.1393
-5,000
ceo, president, chairman
Dec 18, 2023
susi roger e.
sold
-220,402
44.0805
-5,000
ceo, president, chairman
Dec 14, 2023
hawkins james b
acquired
42,085
9.84
4,277
-
Dec 14, 2023
hawkins james b
sold
-190,687
44.5843
-4,277
-
Dec 13, 2023
hawkins james b
acquired
51,355
9.84
5,219
-
Dec 13, 2023
hawkins james b
sold
-223,540
42.8319
-5,219
-
Dec 12, 2023
susi roger e.
sold
-214,113
42.8226
-5,000
ceo, president, chairman

1–10 of 50

Which funds bought or sold IRMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC Financial Services Group, Inc.
sold off
-100
-2,130
-
-%
Mar 11, 2024
VANGUARD GROUP INC
added
3.57
1,976,620
20,263,800
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
92.89
2,646,550
5,134,640
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.41
10,600
172,506
-%
Feb 23, 2024
CIM, LLC
new
-
395,621
395,621
0.06%
Feb 15, 2024
Farther Finance Advisors, LLC
unchanged
-
74.00
1,139
-%
Feb 15, 2024
Legal & General Group Plc
added
2.82
39,155
430,364
-%
Feb 15, 2024
State of Wyoming
reduced
-46.5
-30,071
40,255
0.01%
Feb 15, 2024
BARCLAYS PLC
added
83.16
454,000
926,000
-%
Feb 14, 2024
Ballast Asset Management, LP
added
44.39
606,398
1,719,550
1.09%

1–10 of 46

Are Funds Buying or Selling IRMD?

Are funds buying IRMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IRMD
No. of Funds

Unveiling iRadimed Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
susi roger e.
36.4%
4,587,950
SC 13G/A
Feb 12, 2024
nine ten capital management llc
6.3%
799,366
SC 13G/A
Feb 09, 2024
blackrock inc.
5.2%
651,948
SC 13G
Feb 02, 2024
soleus capital master fund, l.p.
5.1%
641,706
SC 13G/A
Feb 14, 2023
soleus capital master fund, l.p.
5.9%
742,004
SC 13G/A
Feb 13, 2023
renaissance technologies llc
4.73%
594,312
SC 13G/A
Feb 10, 2023
nine ten capital management llc
6.2%
781,766
SC 13G/A
Sep 01, 2022
soleus capital master fund, l.p.
5.1%
646,411
SC 13G
Feb 11, 2022
renaissance technologies llc
5.62%
693,312
SC 13G/A
Feb 09, 2022
nine ten capital management llc
5.9%
730,659
SC 13G/A

Recent SEC filings of iRadimed Corp

View All Filings
Date Filed Form Type Document
Mar 01, 2024
10-K
Annual Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G
Major Ownership Report
Feb 08, 2024
8-K
Current Report
Feb 02, 2024
SC 13G/A
Major Ownership Report
Dec 27, 2023
4
Insider Trading
Dec 22, 2023
4
Insider Trading
Dec 20, 2023
4
Insider Trading

What is the Fair Value of IRMD?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to iRadimed Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.9B
40.1B
-3.02% 19.11%
34.4
4.91
-8.12% -17.45%
71.2B
19.5B
2.28% 4.53%
56.69
3.65
4.02% -22.04%
24.6B
3.9B
3.45% 0.50%
55.33
6.38
3.42% 23.09%
21.7B
14.8B
1.75% 11.60%
8.16
1.46
2.12% 209.17%
MID-CAP
10.2B
2.7B
2.92% -30.26%
-16.04
3.83
-4.68% 82.43%
9.7B
12.3B
-3.34% -3.19%
23.21
0.78
-2.44% -22.68%
9.5B
3.5B
2.97% 25.27%
33.57
2.74
4.97% 18.89%
6.9B
4.0B
-2.47% -11.08%
-51.36
1.74
1.10% 85.84%
3.5B
366.4M
0.74% 28.92%
-577.22
9.59
33.86% 89.80%
2.5B
6.6B
-3.84% 3.03%
12.86
0.38
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
47.53% -25.51%
-2.23
0.47
7.73% -1066.14%
379.3M
166.7M
5.16% -2.53%
-4.59
2.28
6.67% -456.34%
227.2M
329.5M
-13.41% -54.45%
-16.09
0.69
0.49% 64.22%
43.3M
52.3M
-46.12% -38.06%
-2.31
0.83
17.61% 19.28%
4.5M
3.7M
2.40% 338.46%
-0.37
1.19
5.77% 8.23%

iRadimed Corp News

Latest updates
CNN • 23 Mar 2024 • 12:23 pm
MarketBeat • 18 Mar 2024 • 09:54 pm
Yahoo Finance • 13 Mar 2024 • 07:00 am
Quartz • 08 Feb 2024 • 08:00 am
Simply Wall St • 07 Feb 2024 • 08:00 am
Seeking Alpha • 01 Feb 2024 • 08:00 am
Seeking Alpha • 4 months ago

iRadimed Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue5.7%17,45216,50516,13015,47514,86413,40712,72212,31111,87310,9079,8109,2248,5467,6996,7958,67810,8919,9639,2268,4388,339
Cost Of Revenue10.1%4,0393,6673,9443,7543,6432,8652,5822,9312,6232,5022,4782,1622,1071,9581,8652,2142,7422,1681,8582,0481,982
Gross Profit4.5%13,41312,83712,18611,72111,22010,54310,1409,3809,2508,4067,3327,0626,4395,7414,9306,4648,1497,7957,3676,3906,357
Operating Expenses19.1%8,2536,9327,2237,7146,9676,4105,9736,3056,1405,3195,4885,2855,7884,9567,8595,7275,9105,2764,9924,8764,564
  S&GA Expenses16.2%3,3292,8642,9483,0003,6653,0372,9083,0703,1212,5862,4702,3793,0692,2822,3742,4342,5622,2972,2002,1112,049
  R&D Expenses43.7%650453962794605492663519495481454476513477483430379370331353368
EBITDA Margin4.8%0.34*0.33*0.31*0.32*0.32*0.32*0.32*0.28*0.27*0.23*0.18*0.05*---------
Income Taxes-14.9%1,1421,3411,1199441,030810939573-77951838838427.00-280-798-933-887174365-239169
Earnings Before Taxes-11.3%5,6826,4095,2984,3504,7044,2374,1803,0603,1133,0941,8571,771665794-2,9118362,3542,6292,4541,6061,876
EBT Margin0.6%0.33*0.33*0.31*0.31*0.30*0.29*0.28*0.25*0.24*0.19*0.14*0.01*---------
Net Income-10.4%4,5405,0674,1803,4063,6743,4273,2412,4873,8932,5761,4701,3876371,075-2,1121,7693,2422,4552,0891,8461,707
Net Income Margin1.1%0.26*0.26*0.25*0.24*0.24*0.26*0.26*0.23*0.22*0.16*0.13*0.03*---------
Free Cashflow211.7%3,3811,0853,309-1,7492,7813,7461,4511,2433,2753,2283,462811---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets5.4%92.0087.0081.0076.0086.0080.0076.0072.0083.0078.0076.0072.0071.0070.0069.0068.0067.0063.0057.0054.0048.00
  Current Assets5.7%76.0072.0066.0061.0077.0072.0068.0066.0076.0072.0069.0065.0064.0063.0060.0061.0059.0056.0050.0047.0045.00
    Cash Equivalents6.5%50.0047.0046.0043.0058.0056.0052.0050.0062.0058.0055.0051.0050.0048.0045.0045.0043.0039.0032.0030.0028.00
  Inventory9.9%13.0012.008.006.005.005.005.004.004.004.004.005.004.005.005.004.004.004.004.004.004.00
  Net PPE4.5%9.009.009.009.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.00
Liabilities61.5%21.0013.0012.0011.0012.0010.0010.0010.0011.0011.0011.009.0010.0010.0010.0010.0011.0011.0010.0010.006.00
  Current Liabilities107.1%16.008.008.007.009.006.006.006.007.006.006.005.005.005.005.005.006.006.005.005.005.00
Shareholder's Equity-4.2%71.0075.0069.0064.0074.0070.0066.0063.0072.0068.0065.0063.0061.0061.0058.0058.0056.0052.0047.0045.0042.00
  Retained Earnings-7.4%43.0047.0042.0037.0047.0044.0040.0037.0047.0043.0041.0039.0038.0037.0036.0038.0036.0033.0031.0029.0027.00
  Additional Paid-In Capital1.0%28.0028.0027.0027.0026.0026.0026.0026.0025.0025.0024.0024.0024.0024.0022.0020.0019.0019.0017.0016.0015.00
Shares Outstanding0.5%13.0013.0013.0013.0013.0013.0013.0013.0012.0012.0012.0012.00---------
Float-------242---185---146---107--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations180.9%3,9121,3933,5144,6463,0393,9381,6391,4263,3663,3783,5719432,4961,3347911,1973,9493,1382,4806653,542
  Share Based Compensation3.2%551534568534427393121453392777-57.563483184172,659569549456468382402
Cashflow From Investing-44.1%-632-439-378-6,557-471-55678.00-424260-220783-173301-110287-2309351,3693395571,074
Cashflow From Financing-737.1%-262-31.37-89.77-13,272-19852.00-5.72-12,5542.0054.004.00-36.25-277868-256188-39.951,708-82.20434-288
  Dividend Payments----13,223---12,559-------------

IRMD Income Statement

2023-12-31
STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
STATEMENTS OF OPERATIONS  
Revenue$ 65,562,296$ 53,303,145
Cost of revenue15,404,02712,020,742
Gross profit50,158,26941,282,403
Operating expenses:  
General and administrative15,122,06510,697,067
Sales and marketing12,142,09012,679,610
Research and development2,858,6562,278,081
Total operating expenses30,122,81125,654,758
Income from operations20,035,45815,627,645
Other income, net1,702,798553,104
Income before provision for income taxes21,738,25616,180,749
Provision for income tax expense4,545,4803,352,262
Net income$ 17,192,776$ 12,828,487
Net income per share:  
Basic (in dollars per share)$ 1.36$ 1.02
Diluted (in dollars per share)$ 1.35$ 1.02
Weighted average shares outstanding:  
Basic (in shares)12,602,94812,562,856
Diluted (in shares)12,722,53012,635,971

IRMD Balance Sheet

2023-12-31
BALANCE SHEETS - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 49,762,198$ 57,960,864
Accounts receivable, net of allowance for doubtful accounts of $368,835 as of December 31, 2023, and $160,498 as of December 31, 202212,224,27313,274,521
Inventory, net12,821,1945,369,233
Prepaid expenses and other current assets1,193,447630,960
Prepaid income taxes 254,093
Total current assets76,001,11277,489,671
Property and equipment, net9,288,6252,399,812
Intangible assets, net2,519,0532,069,439
Operating lease right-of-use asset2,043,0432,205,286
Deferred tax asset, net2,122,816700,867
Other assets181,449648,672
Total assets92,156,09885,513,747
Current liabilities:  
Accounts payable1,857,0911,799,316
Accrued payroll and benefits2,775,1032,871,890
Other accrued taxes103,241121,919
Warranty reserve117,46394,030
Deferred revenue2,570,4073,373,122
Dividend payable7,975,997 
Current portion of operating lease liabilities427,963293,466
Other current liabilities250,000 
Accrued income taxes250,041 
Total current liabilities16,327,3068,553,743
Deferred revenue2,793,5481,375,197
Operating lease liabilities, less current portion1,615,0801,911,820
Total liabilities20,735,93411,840,760
Stockholders' equity:  
Common stock; $0.0001 par value; 31,500,000 shares authorized; 12,660,313 shares issued and outstanding as of December 31, 2023, and 12,591,004 shares issued and outstanding as of December 31, 20221,2651,259
Additional paid-in capital28,160,74526,407,446
Retained earnings43,258,15447,264,282
Total Stockholders' Equity71,420,16473,672,987
Total liabilities and stockholders' equity$ 92,156,098$ 85,513,747
IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
 CEO
 WEBSITEwww.iradimed.com
 EMPLOYEES123

iRadimed Corp Frequently Asked Questions


What is the ticker symbol for iRadimed Corp? What does IRMD stand for in stocks?

IRMD is the stock ticker symbol of iRadimed Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iRadimed Corp (IRMD)?

As of Wed Mar 27 2024, market cap of iRadimed Corp is 549.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IRMD stock?

You can check IRMD's fair value in chart for subscribers.

What is the fair value of IRMD stock?

You can check IRMD's fair value in chart for subscribers. The fair value of iRadimed Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iRadimed Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iRadimed Corp a good stock to buy?

The fair value guage provides a quick view whether IRMD is over valued or under valued. Whether iRadimed Corp is cheap or expensive depends on the assumptions which impact iRadimed Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IRMD.

What is iRadimed Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, IRMD's PE ratio (Price to Earnings) is 31.94 and Price to Sales (PS) ratio is 8.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRMD PE ratio will change depending on the future growth rate expectations of investors.